Alkermes Q2 2023 Earnings Report

Alkermes EPS Results

• Actual EPS: $0.38
• Consensus EPS: $0.28
• Beat/Miss: Beat by +$0.10
• One Year Ago EPS: N/A

Alkermes Revenue Results

• Actual Revenue: $617.40 million
• Expected Revenue: $572.57 million
• Beat/Miss: Beat by +$44.83 million
• YoY Revenue Growth: N/A

Alkermes Announcement Details

• Quarter: Q2 2023
• Date: 7/26/2023
• Time: N/A

Alkermes (NASDAQ:ALKS), a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ARISTADA INITIO for the treatment of schizophrenia in adults; VIVITROL for the treatment of alcohol and prevention of opioid dependence; and LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. The company also offers proprietary technology platforms to third parties to enable them to develop, commercialize, and manufacture products. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.